Evidence map›Paper›PMID 41963623›Full record

ArticleCommunications biology2026

Elovanoid neuroprotection targets cell transcriptomics and proteomics to sustain synaptic integrity after brain injury.

Brian L Giles, Surjyadipta Bhattacharjee, Jeff X Ji, Pranab K Mukherjee, Ludmila Belayev, Carlos M Vieira, Nicolas G Bazan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brian L Giles *Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.
Surjyadipta Bhattacharjee *Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.ORCID http://orcid.org/0000-0003-0185-553X
Jeff X Ji *Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.
Pranab K MukherjeeNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.
Ludmila BelayevNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.
Carlos M VieiraNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA.
Nicolas G BazanNeuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA. nbazan@lsuhsc.edu.ORCID http://orcid.org/0000-0002-9243-5444

Funding

Translational Genomics Core (TGC)P20GM121288 · NIGMS · LSU HEALTH SCIENCES CENTER · PI Arunava Roy · 2017 to 2026
$22.4M
Neuroprotective lipid mediators target penumbra in experimental ischemic strokeR01NS138259 · NINDS · LSU HEALTH SCIENCES CENTER · PI Nicolas G. Bazan, Ludmila S. Belayev · 2024 to 2026
$1.5M
NIGMS NIH HHS P20 GM121288NINDS NIH HHS R01 NS138259U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS138259
6 · The paper itself

Abstract

Traumatic brain injury (TBI), a leading cause of death and disability, is the largest non-genetic, non-aging-related contributor to cognitive impairments. Currently, there are limited effective therapies to protect neurons after acute brain injury. Our results suggest that intranasal-delivered (IN) elovanoid (ELV) shortly after TBI elicits neuroprotection that involves synaptic and mitochondrial pathways that mediate neuroprotection. Using a single-cell multiome approach, we found an upregulation of genes involved in synaptic integrity. Furthermore, we discovered that ELVs improve synaptosomal mitochondrial function, reduce lipid peroxidation, and increase the activity of antioxidant transcriptional programs, including the NRF2 pathway, in neurons. We suggest that these changes, together with the induction of cell-type-specific gene regulation in glutamatergic neurons and other cells, underlie ELV-elicited neuroprotection.

Indexed as

Brain InjuriesBrain Injuries, TraumaticNeuroprotectionNeuroprotective AgentsProteomicsSynapsesTranscriptomeAnimalsGene Expression ProfilingMiceMitochondriaNeuronsNeuroprotective Agents

Identifiers

PMID41963623
PMCPMC13365245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.